(Q33873118)

29 July 2017

1 reference

title

Cetuximab therapy for head and neck squamous cell carcinoma: a systematic review of the data (English)

1 reference

head and neck squamous cell carcinoma

29 July 2017

1 reference

1 reference

1 reference

Travis D Reeves

1

1 reference

29 July 2017

Elizabeth G Hill

series ordinal

2

1 reference

29 July 2017

Kent E Armeson

series ordinal

3

1 reference

29 July 2017

M Boyd Gillespie

series ordinal

4

1 reference

29 July 2017

1 May 2011

1 reference

Otolaryngology—Head and Neck Surgery

29 July 2017

1 reference

29 July 2017

144

1 reference

29 July 2017

5

1 reference

29 July 2017

676-684

1 reference

Targeted therapies in squamous cell carcinoma of the head and neck

29 July 2017

1 reference

https://api.crossref.org/works/10.1177%2F0194599811399559

EGFR antagonists in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0194599811399559

Cetuximab in squamous cell head and neck carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0194599811399559

New approaches to enhance chemotherapy in SCCHN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0194599811399559

Meta-analysis: formulating, evaluating, combining, and reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0194599811399559

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0194599811399559

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0194599811399559

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0194599811399559

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0194599811399559

Platinum-based chemotherapy plus cetuximab in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0194599811399559

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0194599811399559

Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0194599811399559

Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0194599811399559

Human papillomavirus in cervical and head-and-neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0194599811399559

Cystic lymph node metastasis in patients with head and neck cancer: An HPV-associated phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0194599811399559

Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0194599811399559

Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0194599811399559

Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0194599811399559

Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0194599811399559

Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0194599811399559

Combined cetuximab and reirradiation for locoregional recurrent and inoperable squamous cell carcinoma of the head and neck.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0194599811399559

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0194599811399559

21 January 2018

Identifiers

DOI

10.1177/0194599811399559

1 reference

29 July 2017

1 reference